Toxicity of a first-generation adenoviral vector in rhesus macaques

Human Gene Therapy

Volumn 13, Issue 1, 2002, Pages 113-124

  Lozier, Jay N ^a   Csako, Gyorgy ^b   Mondoro, Traci H ^c   Krizek, D M ^b   Metzger, Mark E ^d   Costello, Rene ^b   Vostal, Jaroslav G ^c   Rick, M E ^b   Donahue, Robert E ^d   Morgan, Richard A ^e  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SCREENING; FEMALE; GENE TRANSFER; GRANULOCYTOSIS; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERAMYLASEMIA; LABORATORY TEST; LYMPHOCYTOSIS; NONHUMAN; ORGAN; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; RAT; TISSUE DISTRIBUTION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS SHEDDING;

ADENOVIRUSES, HUMAN; ANIMALS; BLOOD CELL COUNT; CREATINE KINASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR IX; FIBRINOGEN; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS; INTERLEUKIN-6; ISOENZYMES; L-LACTATE DEHYDROGENASE; LIVER; MACACA MULATTA; MUSCLE, SKELETAL; PLATELET AGGREGATION; VON WILLEBRAND FACTOR;

ADENOVIRIDAE; ANIMALIA; MACACA; MACACA MULATTA; PRIMATES; SIMPLEXVIRUS;

EID: 0036147236     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152712665     Document Type: Article

References (39)

1. Adeno-retroviral chimeric viruses as in vivo transducing agents
2. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and non-human primate lung
3. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
4. Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation
5. Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression
6. Acute-phase proteins and other systemic responses to inflammation
7. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: Applicability to hemophilia A gene therapy
8. Adenoviruses
9. Gene-environment interactions in the determination of levels of plasma fibrinogen
10. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors
11. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat
12. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
13. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
14. Proceedings: A more uniform measurement of factor VIII inhibitors
15. Minutes of symposium and meeting, recombinant DNA advisory committee, December 8-10, 1999
16. A rapid method to visualize von Willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection
17. Virus treatment questioned after gene therapy death
18. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFkappaB
19. Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes
20. Gut epithelial cells as targets for gene therapy of hemophilia
21. The rhesus macaque as an animal model for hemophilia B gene therapy
22. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
23. Kinetics of recombinant adeno-associated virus-mediated gene transfer
24. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
25. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha-1-antitrypsin with negligible toxicity
26. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
27. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis
28. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
29. Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor
30. Evaluation of adenoviral vectors for treatment of hemophilia A: Demonstration of an unexpected, non-linear in vivo dose response
31. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
32. 100Escherichia coli in the baboon
33. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
34. C4b-binding protein exacerbates the host response to Escherichia coli
35. Comparative sequence analysis of cytokine genes from human and non-human primates
36. Successful expression of human factor IX following repeat administration of an adenoviral vector in mice
37. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13
38. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
39. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs